Leukemia Clinical Trials

Narrow List by Age:

(Refer to Clinical Summary for age requirements)

Leukemia

Protocol Alliance A041501
Cancer Type: NEWLY DIAGNOSED PRECURSOR B-CELL ALL
Fast Facts

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL

Protocol COG ACCL1931
Cancer Type: ALL
Fast Facts

COG-ACCL1931: A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy

Age: ≥15 and <40 years at time of diagnosis.

Protocol COG AALL2121
Cancer Type: leukemia
Fast Facts

COG-AALL2121: A Phase 2 study of SNDX-5613 in combination with chemotherapy for patients with relapsed or refractory KMT2A-rearranged infant leukemia

Age: Patients must be 1 month to < 6 years old at the time of study enrollment and must have had initial diagnosis of leukemia at < 2 years old.

Please check out the rare protocol list to locate other studies within this disease site.

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1925
Cancer Type: CLL/SLL
Fast Facts

RANDOMIZED, PHASE III STUDY OF EARLY INTERVENTION WITH VENETOCLAX AND OBINUTUZUMAB VERSUS DELAYED THERAPY WITH VENETOCLAX AND OBINUTUZUMAB IN NEWLY DIAGNOSED ASYMPTOMATIC HIGH-RISK PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EVOLVE CLL/SLL STUDY

Please check out the rare protocol list to locate other studies within this disease site.

Protocol NHLBI-MDS
Cancer Type: Myelodysplastic Syndromes
Fast Facts

The National Myelodysplastic Syndromes (MDS) Study

Please check out the rare protocol list to locate other studies within this disease site.

Protocol COG AALL1621
Cancer Type: Relapsed Refractory CD22 B-ALL
Fast Facts

A Phase II Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

Patients must be ≥1 Year and < 22 Years of Age at the Time of Enrollment.

Protocol COG AALL1631
Cancer Type: Ph+ ALL
Fast Facts

International Phase III Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones

Age:  > 1 Year and < 21 Years at ALL Diagnosis

Protocol COG AALL1731
Cancer Type: B-ALL, B-LLy
Fast Facts

A Phase III Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)

Patients must be ≥ 365 Days and < 10 Years of Age (B-ALL Patients without DS)

Patients must be ≥ 365 Days and ≤ 31 Years of Age (B-ALL Patients with DS)

Patients must be ≥ 365 Days and ≤ 31 Years of Age (B-LLy Patients with or without DS

 

Protocol COG AALL1732
Cancer Type: B-ALL, B-LLy
Fast Facts

A Phase III Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL,Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Patients must be > 365 Days and < 25 Years of Age

Protocol COG AAML18P1
Cancer Type: Chronic Myeloid Leukemia
Fast Facts

COG AAML18P1

Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)

Patient must have been diagnosed with CML-CP at less than 18 years of age

Patient mustbe less than 25 years of age at enrollment

Protocol COG APAL2020SC
Cancer Type: Relapsed Leukemia
Fast Facts

COG APAL2020SC

Pediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias

Patients must be less than 22 years of age at the time of study enrollment.

Protocol COG ASCT2031
Cancer Type: leukemia
Fast Facts

COG-ASCT2031: A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) with Acute Leukemia or Myelodysplastic Syndrome (MDS)

Age: 6 months to <22 years at enrollment

Please check out the rare protocol list to locate other studies within this disease site.

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.